AIM ImmunoTech (NYSEMKT:AIM) announces that the U.S. Department of Defense (DoD) has granted a four-year, $6.42M “Breakthrough Award" to Roswell Park Comprehensive Cancer Center for a clinical study of a combination of therapies, in patients with brain-metastatic breast cancer.
Shares are up 105% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.